What development phase is SULFAQUINOXALINE in?

SULFAQUINOXALINE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

SULFAQUINOXALINE

FDA-approved active Small molecule Quality 6/100

Sulfaquinoxaline is a marketed drug with an unclear mechanism of action, primarily used in treating specific conditions, though the primary indication is not specified. The key strength lies in its current market presence, which is protected until 2028 by a key composition patent. The primary risk is the lack of a well-understood mechanism, which may limit further development and regulatory support.

At a glance

Generic name	SULFAQUINOXALINE
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.